ALK and non-small cell lung carcinoma: Alectinib has demonstrated significant effectiveness as an adjuvant therapy in completely resected stage IB, II, and IIIA ALK-positive NSCLC, showing a marked improvement in disease-free survival when compared with chemotherapy options.